Platelet and Plasma Market Size, Share, Growth, and Industry Analysis, By Type (Platelet,Plasma), By Application (Hemophilia,Thrombocytopenia,Perioperative Indications,Platelet Function Disorders,Other Platelet Applications,Coagulation Factor Deficiencies,Thrombotic Thrombocytopenic Purpura,Hemorrhage,Liver Disease), Regional Insights and Forecast to 2035

Platelet and Plasma Market Overview

The global Platelet and Plasma Market size is projected to grow from USD 6548.18 million in 2026 to USD 6713.19 million in 2027, reaching USD 7989.39 million by 2035, expanding at a CAGR of 2.52% during the forecast period.

The Platelet and Plasma Market Market represents one of the most vital components in global healthcare infrastructure, serving transfusion medicine, surgical care, and plasma-derived therapeutic manufacturing. In 2024, global platelet and plasma demand exceeded 120 million blood component units, with plasma accounting for approximately 45 percent and platelets about 30 percent of total transfusion volumes. More than 40 percent of blood donations originate from high-income countries, which collectively represent only 16 percent of the global population. Approximately 20 million liters of plasma are fractionated annually to produce immunoglobulins, albumin, and clotting factor concentrates, accounting for more than 70 percent of total plasma usage. The Platelet and Plasma Market Industry Analysis indicates rising global need for apheresis platelets and pathogen-reduced plasma to maintain transfusion safety and supply reliability.

In the United States, platelet and plasma demand is among the highest globally, supported by robust healthcare infrastructure and advanced transfusion practices. Around 2.5 million platelet units and nearly 6 million plasma units are transfused annually. Approximately 11.7 million blood donations are collected each year, of which 60 percent are processed into plasma and platelet components. About 75 percent of U.S. plasma collections are derived from voluntary donors, while 25 percent originate from compensated donations. Pathogen reduction technologies are applied to nearly 20 percent of platelet units, ensuring compliance with safety standards. The Platelet and Plasma Market Market Report identifies the U.S. as a leading region in both platelet automation and plasma fractionation capacity, contributing more than one-third of total global plasma supply.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 45 % of global transfusions involve plasma components supporting life-saving therapies
• Major Market Restraint: 15 % wastage rate from expired or unusable platelet and plasma units
• Emerging Trends: 30 % of plasma redirected to plasma-derived pharmaceutical manufacturing
• Regional Leadership: North America holds 35 % share of platelet and plasma production systems
• Competitive Landscape: Top 5 national blood services handle over 50 % of global component supply
• Market Segmentation: Platelets represent 30 % and plasma 45 % of transfused blood components worldwide
• Recent Development: Pathogen-reduction technology expanded to 18 % of platelet collections globally

Platelet and Plasma Market Latest Trends

The latest Platelet and Plasma Market Market Trends highlight rapid adoption of automation, precision apheresis, and increasing use of pathogen inactivation systems. Plasma fractionation facilities processed more than 20 million liters of plasma globally in 2024, with 70 percent allocated to immunoglobulin and clotting factor production. Platelet component production grew by approximately 8 percent over the previous year, supported by oncology and surgical demand. Approximately 25 percent of global platelet collections now originate from apheresis rather than pooled whole blood, improving component safety. Hospitals in developed economies extended platelet shelf life from five to seven days, enhancing availability by nearly 10 percent. PRP (platelet-rich plasma) therapy accounted for around 10 percent of platelet usage, particularly in orthopedics and dermatology.

Platelet and Plasma Market Dynamics

DRIVER

"Rising demand for plasma-derived therapies and advanced transfusion systems"

Global healthcare reliance on plasma-derived products has expanded rapidly, as immunoglobulin and albumin therapies are increasingly prescribed for chronic conditions. Approximately 60 percent of collected plasma is redirected for fractionation, supporting treatment for more than 100 different medical conditions. Transfusion demand for platelets increased by nearly 9 percent in the last three years, driven by oncology, trauma, and cardiac surgery patients. Automation in plasma separation improved collection throughput by 18 percent and reduced manual error by 25 percent. The Platelet and Plasma Market Market Analysis identifies plasma fractionation expansion in high-income countries as a major growth driver, with several facilities processing over 1 million liters annually.

RESTRAINT

"Limited donor base and component shelf life constraints"

Global donor participation remains limited, with fewer than 5 percent of eligible individuals donating blood annually. In developing regions, donation rates average 5 units per 1,000 people compared to 31 per 1,000 in high-income nations. Platelet shelf life is restricted to five days, leading to wastage rates between 10 and 15 percent in many hospitals. Plasma discard rates remain around 12 percent due to testing failures or delayed processing. Donor retention challenges persist, as nearly 40 percent of first-time donors fail to return within one year. Infrastructure costs are high, with plasma fractionation and pathogen testing consuming up to 20 percent of total operating budgets.

OPPORTUNITY

"Expansion in emerging markets and growth of platelet-rich plasma therapies"

Emerging economies across Asia-Pacific, Latin America, and Africa offer significant untapped potential. Increasing blood donation rates from 5 to 10 per 1,000 people could double plasma and platelet availability in these regions. The Platelet and Plasma Market Market Opportunities analysis indicates that PRP therapy usage has expanded by more than 25 percent annually across orthopedic, cosmetic, and regenerative medical applications. Mini plasma fractionation units, processing around 5,000 liters per month, are being adopted in secondary cities to meet domestic demand. Investments in automated apheresis devices increased by 20 percent between 2023 and 2025, boosting component yield by up to 30 percent. Local production initiatives could reduce import dependency by 10–15 percent over the next decade.

CHALLENGE

"Regulatory compliance and supply chain vulnerability"

Regulatory frameworks for plasma fractionation and blood component handling vary significantly between countries, causing delays in product approvals and cross-border plasma shipments. Nearly 25 percent of planned plasma processing centers face delays in obtaining regulatory clearances. Quality variation is a concern—approximately 5 percent of plasma units and 3 percent of platelet units fail potency testing annually. Supply chain fragility arises from overdependence on a few donor nations; five countries collectively supply 80 percent of global fractionated plasma volume. Logistical losses due to inadequate refrigeration or transport conditions average 3–4 percent globally. Skilled personnel shortages are notable, with nearly 15 percent of blood centers reporting technical vacancies.

Platelet and Plasma Market Segmentation

The Platelet and Plasma Market Market is divided by type and application, forming the foundation for evaluating operational performance and strategic direction in the Platelet and Plasma Market Industry Report.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Platelet: Platelet products represent about 30 percent of total global blood component transfusions. Nearly 65 percent are collected through apheresis, while 35 percent come from pooled whole blood. Global output exceeds 10 million units annually. Shelf life remains limited to 5–7 days, with wastage near 12 percent. Around 18 percent of platelet units are pathogen reduced, and 10 percent are used for platelet-rich plasma (PRP) applications.

Plasma: Plasma accounts for around 45 percent of transfused blood components worldwide. About 60 percent of plasma is processed for fractionation, producing immunoglobulins and coagulation factors. Annual global processed plasma exceeds 20 million liters, with efficiency levels between 80 and 85 percent. Average discard rates stand at 15 percent, and 30 percent of plasma supports surgical or trauma-related transfusions.

BY APPLICATION

Hemophilia: Accounts for around 25 percent of total plasma use globally. Each patient requires approximately 2–3 plasma-equivalent units annually for factor replacement therapy.

Thrombocytopenia: Represents about 15 percent of platelet transfusions worldwide, primarily used in oncology and bone marrow transplant patients.

Perioperative indications: Consume nearly 10 percent of plasma volume for surgical and trauma procedures, especially in cardiac and liver transplant operations.

Platelet function disorders: Represent approximately 5 percent of platelet transfusion demand, mainly during acute bleeding events and invasive procedures.

Other platelet applications: Include PRP (platelet-rich plasma) therapies, contributing nearly 10 percent of global platelet use in orthopedics and regenerative treatments.

Coagulation factor deficiencies: Account for about 8 percent of plasma usage across hematology centers for factor V, VII, and XI replacement therapies.

Thrombotic Thrombocytopenic Purpura (TTP): Uses around 3 percent of global plasma volume through therapeutic plasma exchange protocols.

Hemorrhage: Represents 20–25 percent of total plasma consumption globally for emergency trauma and obstetric bleeding cases.

Liver disease: Covers approximately 12 percent of plasma transfusions for coagulation correction in liver failure and transplant procedures.

Platelet and Plasma Market Regional Outlook

North America leads in platelet and plasma collection and processing capacity Europe maintains the strongest regulatory and technical infrastructure for fractionation Asia-Pacific is rapidly expanding donation and plasma separation systems Middle East & Africa remains underdeveloped but shows growing donor recruitment programs

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America represents around 35 percent of the global Platelet and Plasma Market Market share. The United States contributes approximately 75 percent of regional plasma volume, with Canada and Mexico accounting for the remaining 25 percent. Annual collections exceed 11 million donations, producing over 2.5 million platelet units and 6 million plasma units. Around 65 percent of centers utilize automated apheresis systems, and 20 percent of platelet collections undergo pathogen inactivation. The Platelet and Plasma Market Report identifies North America as the leading region for donor safety systems and high-throughput fractionation capacity.

EUROPE

Europe accounts for approximately 28 percent of global platelet and plasma utilization. France, Germany, Italy, and Spain dominate regional collections, contributing over 70 percent of total volume. Approximately 30 percent of European plasma is processed into fractionated pharmaceuticals, while 40 percent supports transfusion therapy. Barcoded donor identification and traceability are universal, ensuring 99 percent compliance in component tracking. About 15 percent of platelet units undergo pathogen reduction treatment, and average discard rates are below 10 percent. The Platelet and Plasma Market Analysis notes that Europe remains the benchmark for transfusion safety and sustainability.

ASIA-PACIFIC

Asia-Pacific holds about 20 percent of global platelet and plasma demand, reflecting accelerating healthcare investment and infrastructure development. Regional blood donation rates increased by 12–15 percent between 2023 and 2025, led by China, India, and Australia. Annual plasma processing capacity across the region now exceeds 5 million liters. Around 60 percent of regional collections are directed toward fractionation, while 40 percent are used for direct transfusion. The Platelet and Plasma Market Outlook highlights rapid PRP adoption across Asia-Pacific, accounting for 20 percent of global PRP procedures.

MIDDLE EAST & AFRICA

Middle East & Africa account for around 5 percent of global platelet and plasma collection. South Africa represents nearly 40 percent of this regional capacity, while North African countries contribute 30 percent. Annual donations remain below 10 per 1,000 people, creating supply gaps. Regional transfusion services rely on imports for 60 percent of plasma-derived therapies. Infrastructure investments have improved by 15 percent in the past three years, especially in Saudi Arabia, Egypt, and South Africa. Donor recruitment initiatives have increased participation by 10 percent annually.

List of Top Platelet and Plasma Companies

• Red Cross Society of China
• German Red Cross
• South African Red Cross Society
• Saudi Red Crescent Authority
• Italian Red Cross
• Brazilian Red Cross
• Indian Red Cross
• Canadian Red Cross
• French Red Cross
• European Blood Alliance
• America’s Blood Centers
• American Red Cross

Top 2 Companies:

American Red Cross: Handles approximately 30 percent of the total platelet and plasma collection volume in the U.S. and operates one of the world’s largest blood supply chains. It manages an estimated 6 million plasma units and 2.5 million platelet units per year. European Blood Alliance: Coordinates national blood services across more than 25 European nations, collectively managing about 25 percent of the continent’s plasma and platelet output, ensuring supply stability through shared fractionation and donor frameworks.

Investment Analysis and Opportunities

Global investment in the Platelet and Plasma Market Market is focusing on automation, pathogen reduction, and infrastructure modernization. Around 15–20 percent of global health infrastructure funding between 2025 and 2030 will target blood safety and plasma processing. Emerging markets in Asia-Pacific and Latin America are developing local fractionation units capable of processing 5,000 liters of plasma monthly. Investment in apheresis equipment is growing by 12 percent annually, increasing plasma yield by up to 25 percent. Private transfusion service providers are capturing 10 percent of regional supply networks in several middle-income countries.

New Product Development

Product innovation in the Platelet and Plasma Market Market focuses on enhancing safety, yield, and accessibility. Extended shelf-life platelet storage systems increased usable lifespan from 5 to 7 days, improving availability by 10 percent. Closed-system plasma fractionation modules reduced contamination risk by 25 percent. Freeze-dried plasma formulations demonstrated 80 percent recovery efficiency, enabling use in emergency and military medicine. Automated PRP preparation devices expanded clinical precision, now present in more than 30 percent of orthopedic clinics globally. Integrated donor management platforms were adopted by 20 percent of blood centers, improving retention by 15 percent. Mobile apheresis units capable of processing 1,000 milliliters per hour were deployed in regional collection centers, enhancing flexibility.

Five Recent Developments

• Automated plasma fractionation lines expanded processing capacity by 20 percent in major centers.
• Pathogen inactivation technologies adopted in 18 percent of platelet units globally.
• Mini fractionation units introduced in Asia-Pacific with 5,000-liter monthly capacity.
• PRP clinical adoption increased by 25 percent across orthopedics and cosmetics.
• Blood collection automation implemented in 15 percent of new donor facilities worldwide.

Report Coverage

The Platelet and Plasma Market Market Report provides detailed coverage of global trends, component segmentation, and regional performance. It includes volume analysis by component type (platelet, plasma), application area (hemophilia, thrombocytopenia, perioperative, platelet function disorders, coagulation factor deficiencies, TTP, hemorrhage, liver disease), and regional distribution (North America, Europe, Asia-Pacific, Middle East & Africa). The Platelet and Plasma Market Market Research Report examines production efficiency, discard rates, donor participation, and plasma processing capacity utilization, which averages between 70 and 90 percent globally. It further explores emerging PRP therapy applications and automation in plasma separation.

Platelet and Plasma Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6548.18 Million in 2026
Market Size Value By	USD 7989.39 Million by 2035
Growth Rate	CAGR of 2.52% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Platelet Plasma By Application : Hemophilia Thrombocytopenia Perioperative Indications Platelet Function Disorders Other Platelet Applications Coagulation Factor Deficiencies Thrombotic Thrombocytopenic Purpura Hemorrhage Liver Disease
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample